GUFICBIOGufic Biosciences Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, and South America. The company manufactures APIs and bulk drugs, such as antifungals, anaethetics, immuno suppressants, anginotensin receptor blocker, and intermediates for antifungals. It also manufactures lyophilized injections for antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs) segments. In addition, the company offers criti care, criticare life, ferticare, and spark pharmaceutical products; and herbal, aesthaderm, gufic stridden, and personal care products. Further, it engages in contract and bulk drug manufacturing business. Gufic Biosciences Limited was founded in 1970 and is based in Mumbai, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
The picture
- • Revenue growth: 22.8% YoY
- • Profit growth: 183.1% YoY
- • Debt/Equity: 0.61
- • Price vs SMA200: above
- • Golden cross setup: SMA50 above SMA200
- • Volume: 1.7x 20-day average
- • Bullish Engulfing signal (setup quality 60%)
Bull case
- • Revenue growth: 22.8% YoY
- • Profit growth: 183.1% YoY
- • Debt/Equity: 0.61
- • Price vs SMA200: above
Bear case
- • ROE: 10.1%
- • Valuation vs sector: P/E 63.5 vs sector 35.5
- • MACD: bearish
- • Price vs EMA21: below
Key risks
- • ROE: 10.1%
- • Valuation vs sector: P/E 63.5 vs sector 35.5
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹18.10). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.